Sustained-Release CBD Microparticle Injection for Month-Long Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis primarily focus on relieving pain and inflammation but do not effectively slow down cartilage degeneration, and existing formulations of cannabidiol require frequent administration to maintain therapeutic levels, lacking convenience and potentially causing side effects.
Innovation Solution
A sustained-release injectable composition using microparticles containing cannabidiol and biodegradable polymers, such as polylactide-co-glycolide, to deliver CBD in a sustained manner for one month or more, minimizing side effects and improving dosing convenience.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional drugs (acetaminophen, NSAIDs, corticosteroids) are used to treat osteoarthritis, then pain and inflammation are relieved, but cartilage damage is accelerated and side effects occur on cardiovascular system, gastrointestinal tract, kidney, and liver
Solution Approach 1:
The patent changes the chemical parameters by using cannabidiol (CBD) instead of conventional drugs like NSAIDs and corticosteroids. CBD provides anti-inflammatory and analgesic effects through different biochemical pathways that do not involve the harmful mechanisms of conventional drugs, thus reducing side effects on cardiovascular system, gastrointestinal tract, kidney, and liver while maintaining therapeutic effectiveness
Solution Approach 2:
The patent creates a composite formulation by encapsulating cannabidiol within microparticles composed of biodegradable polymers (PLGA, PLA). This composite structure allows controlled release of CBD, maintaining effective concentrations while reducing the frequency of administration and minimizing systemic side effects compared to conventional drug formulations
2Reliability
If frequent administration of cannabidiol is used to maintain therapeutic levels, then therapeutic effectiveness is maintained, but dosing convenience is reduced and potential side effects increase
Solution Approach 1:
The patent implements continuous therapeutic action through the sustained-release microparticle formulation. The biodegradable polymer matrix continuously releases cannabidiol over an extended period (weeks to months), maintaining therapeutic blood concentrations without requiring frequent re-dosing. This continuous release mechanism eliminates the need for frequent administration while preserving therapeutic effectiveness
Solution Approach 2:
The patent applies preliminary action by pre-encapsulating the entire monthly or quarterly dose of cannabidiol within microparticles at the time of injection. This single preliminary administration provides sustained release over the intended treatment period, eliminating the need for subsequent dosing events and significantly improving patient convenience
3Ease of operation
If sustained-release formulation using microparticles is used, then dosing convenience is improved and side effects are reduced, but formulation complexity increases
Solution Approach 1:
The patent optimizes formulation parameters by selecting specific biodegradable polymers (PLGA with particular lactide:glycolide ratios, molecular weights, and degradation rates) that balance sustained-release performance with manufacturability. By carefully controlling parameters such as polymer composition, microparticle size distribution, and CBD:polymer ratio, the formulation achieves effective sustained release while maintaining compatibility with conventional manufacturing processes
Solution Approach 2:
The patent uses biodegradable polymers as intermediary carriers that simplify the overall system. These polymers serve as mediators between the drug (cannabidiol) and the biological system, providing controlled release functionality while being metabolized into safe byproducts. This intermediary approach enables sustained-release behavior without requiring complex mechanical delivery systems or external control mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains effective blood concentrations of CBD for extended periods, providing therapeutic benefits for osteoarthritis without frequent injections, reducing side effects and enhancing treatment convenience.
Implementation Method 1
microparticles that release cannabidiol (CBD) in a sustained manner for one month or more, wherein the microparticles may comprise cannabidiol and a biodegradable polymer
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a sustained-release injectable composition for treating or preventing an inflammatory disease, and a method for preparing the same. The present invention may exhibit the effect of treating or preventing inflammatory diseases by releasing cannabidiol in a sustained manner for one month or more using microparticles containing cannabidiol. In addition, the sustained-release injectable composition containing cannabidiol is not toxic, may be used continuously for a long period of time without side effects caused by long-term use, and may exhibit a therapeutic or preventive effect on inflammatory diseases for one month or more by a single injection, thereby significantly improving dosing convenience.